DENIPLANT BIOTECH
Next-Generation Asymmetric Multi-JAK/TYK2 Inhibitors via Botanical Nanomedicine
🔴 The Problem
Current synthetic JAK inhibitors block the immune system non-selectively. This causes severe liver toxicity, damages hematopoiesis (JAK2/JAK3), and creates strong chemical dependency for chronic patients.
🟢 The Solution
A breakthrough portfolio of asymmetric Multi-JAK/TYK2 inhibitors delivered via plant-derived exosomes. We surgically target inflammatory pathways (JAK1/TYK2) while leaving vital immunity fully intact.
⚡ Frontier Technology
Convergence of structural AI (AlphaFold 3), Cryo-EM molecular mapping, and microfluidic self-assembly. Transitioning 30 years of empiric success into a scalable digital drug-discovery pipeline.
📜 IP & Validation
Backed by an existing OSIM Invention Patent from Deniplant’s history. The upcoming next-generation nanotech formulas are being structured for an International Patent (PCT) application.